Organon Acquisition To Supports Sun Pharma’s Specialty Growth Strategy
Sun Pharma is strengthening its innovative medicines and specialty therapies business as the company expands across India, the US and emerging markets. The company’s innovative medicines business crossed $1 billion in the US during FY26, while India formulations grew 14% alongside market share gains. Sun Pharma says the recently announced Organon acquisition is expected to support its global specialty expansion strategy and widen its portfolio. The company is also increasing investments in R&D, specialty products and global markets as it advances multiple molecules across dermatology, oncology and chronic therapies. Demand across India and emerging markets remains steady, while innovative medicines continue to contribute a larger share of revenues.
